Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Vadadustat Formulations in Healthy Adults
NCT03639155Phase 1Completed
- Sponsor
- Akebia Therapeutics
- Start
- Apr 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vadadustat in anemia of chronic kidney disease (CKD-A) (2 arms), sponsored by Akebia Therapeutics. Primary endpoints: Area under plasma concentration-time curve from 0 to last quantifiable concentration at 48 hours, Area under plasma concentration-time curve from 0 to infinity at 48 hours and 2 more. Started Apr 2018; status: completed.
02
Drugs
vadadustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT03639155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03639155.